These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21546628)

  • 1. Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead.
    Tsuji BT; Okusanya OO; Bulitta JB; Forrest A; Bhavnani SM; Fernandez PB; Ambrose PG
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S513-9. PubMed ID: 21546628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection.
    Okusanya OO; Tsuji BT; Bülitta JB; Forrest A; Bulik CC; Bhavnani SM; Fernandes P; Ambrose PG
    Diagn Microbiol Infect Dis; 2011 May; 70(1):101-11. PubMed ID: 21513848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efforts to support the development of fusidic acid in the United States.
    Fernandes P; Pereira D
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S542-6. PubMed ID: 21546632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
    J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin.
    Lemaire S; Van Bambeke F; Pierard D; Appelbaum PC; Tulkens PM
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S493-503. PubMed ID: 21546626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of fusidic acid in therapy of experimental Staphylococcus aureus meningitis.
    Østergaard C; Yieng-Kow RV; Knudsen JD; Frimodt-Møller N; Espersen F
    J Antimicrob Chemother; 2003 May; 51(5):1301-5. PubMed ID: 12697637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States.
    Jones RN; Mendes RE; Sader HS; Castanheira M
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S477-86. PubMed ID: 21546624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Managing children skin and soft tissue infections].
    Moulin F; Quinet B; Raymond J; Gillet Y; Cohen R
    Arch Pediatr; 2008 Oct; 15 Suppl 2():S62-7. PubMed ID: 19000857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus.
    Yu XH; Song XJ; Cai Y; Liang BB; Lin DF; Wang R
    J Antibiot (Tokyo); 2010 Nov; 63(11):657-9. PubMed ID: 20877368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: treatment of chronic osteomyelitis.
    Wolfe CR
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S538-41. PubMed ID: 21546631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.
    Howden BP; Grayson ML
    Clin Infect Dis; 2006 Feb; 42(3):394-400. PubMed ID: 16392088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
    Huang DB; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Desplats E; Torres A
    Int J Antimicrob Agents; 2018 Aug; 52(2):233-240. PubMed ID: 29783024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.
    Van Wart SA; Andes DR; Ambrose PG; Bhavnani SM
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):409-14. PubMed ID: 19249182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling.
    Blumer JL; Reed MD; Kaplan EL; Drusano GL
    Pediatrics; 2005 Oct; 116(4):927-32. PubMed ID: 16199703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the efficacy and toxicity of local fusidic aid versus oral dicloxacillin in infections of the skin].
    Macotela-Ruiz E; Durán Bermúdez H; Kuri Con FJ; Arevalo López A; Villalobos Ibarra JL
    Med Cutan Ibero Lat Am; 1988; 16(2):171-3. PubMed ID: 3050336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus.
    Elliott DJ; Zaoutis TE; Troxel AB; Loh A; Keren R
    Pediatrics; 2009 Jun; 123(6):e959-66. PubMed ID: 19470525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of appropriate antimicrobial dosing: pharmacokinetic and pharmacodynamic considerations.
    Preston SL
    Ann Pharmacother; 2004 Sep; 38(9 Suppl):S14-8. PubMed ID: 15226489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
    Drusano GL
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv33-9. PubMed ID: 21115453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction: fusidic acid enters the United States.
    Moellering RC; Corey GR; Grayson ML
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S467-8. PubMed ID: 21546622
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.